Glaukos submitted an NDA for Epioxa, a novel corneal cross-linking therapy for keratoconus, to the US FDA. Epioxa's Phase 3 ...

Investigators conducted a retrospective clinical audit to determine why patients do not adhere to the guidelines among about 9,000 patients in a practice.

According to Iridex Corp., the study confirms MicroPulse TLT's sustained safety and efficacy in managing glaucoma, reducing ...

THRIVE-2 met all primary and secondary endpoints at the 15-week primary analysis timepoint after 5 infusions of veligrotug.

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

According to the company, its Phase 1/2 CLARA trial of AURN001 for corneal edema demonstrated significant dose-dependent ...

At the FLORetina Conference in Florence, Italy, John W. Kitchens, of Retina Associates of Kentucky, highlighted strategies to enhance efficiency in retina practices, addressing challenges like staff ...

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for. This series features experts in ophthalmology sharing their ...

In an interview with Ophthalmology Times, clinical trial investigator Zaina Al-Mohtaseb MD, noted the CLARA Phase 1/2 trial demonstrated the safety, efficacy, and simplicity of corneal endothelial ...